Grifols SA (GRFS) Price & Analysis

Grifols SA released its earnings results on Jul 29, 2025. The company reported $0.195 earnings per share for the quarter, missing the consensus estimate of $0.226 by -$0.031.

Is Grifols SA overvalued?

According to Wall Street analysts Grifols SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Grifols SA pay dividends?

Grifols SA pays a Annually dividend of $0.142 which represents an annual dividend yield of 1.45%. See more information on Grifols SA dividends here

What is Grifols SA’s EPS estimate?

Grifols SA’s EPS estimate is 0.27.

How many shares outstanding does Grifols SA have?

Grifols SA has 261,425,100 shares outstanding.

What happened to Grifols SA’s price movement after its last earnings report?

Grifols SA reported an EPS of $0.195 in its last earnings report, missing expectations of $0.226. Following the earnings report the stock price went up 4.016%.

Which hedge fund is a major shareholder of Grifols SA?

Currently, no hedge funds are holding shares in GRFS

Grifols SA Stock Smart Score

Outperform

Fundamentals

Return on Equity

5.41%

Trailing 12-Months

Asset Growth

-2.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Grifols SA

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Grifols SA (GRFS) Earnings & Revenues

Historic Earnings Reports

GRFS Company Deck

GRFS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented strong revenue growth, improvements in adjusted EBITDA, and significant free cash flow improvement, highlighting the company's operational resilience and strategic execution. However, challenges such as negative free cash flow due to a one-time payment, phasing impacts in specific segments, and the financial impact of the Inflation Reduction Act were noted. Despite these challenges, the positive aspects of growth and efficiency improvements outweigh the negatives.View all GRFS earnings summaries